Highlights and Quick Summary
- EBITDA for the quarter ending February 28, 2023 was $-2.83 Million (a -135.12% decrease compared to previous quarter)
- Year-over-year quarterly EBITDA decreased by -38.73%
- Annual EBITDA for 2022 was $-14.3 Million (a -70.08% decrease from previous year)
- Annual EBITDA for 2021 was $-47.9 Million (a -49.47% decrease from previous year)
- Annual EBITDA for 2020 was $-94.9 Million (a -974.23% decrease from previous year)
- Twelve month EBITDA ending February 28, 2023 was $-667 Thousand (a 253.1% increase compared to previous quarter)
- Twelve month trailing EBITDA decreased by -96.61% year-over-year
Trailing EBITDA for the last four month:
| 28 Feb '23 | 30 Nov '22 | 31 Aug '22 | 31 May '22 |
|---|---|---|---|
| $-667 Thousand | $-189 Thousand | $-14.3 Million | $-19.7 Million |
Visit stockrow.com/OGI
for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow
statement with 10 years of data, and state-of-the-art screener.
Historical EBITDA of Organigram Holdings Inc.
Most recent EBITDAof OGI including historical data for past 10 years.Interactive Chart of EBITDA of Organigram Holdings Inc.
Organigram Holdings Inc. EBITDA for the past 10 Years (both Annual and Quarterly)
(All values are in $ million)
| Year | Q1 | Q2 | Q3 | Q4 | Fiscal Year |
|---|---|---|---|---|---|
| 2023 | $-2.83 | – | – | – | – |
| 2022 | $8.06 | $-1.28 | $-4.62 | $-2.35 | $-14.34 |
| 2021 | $-6.09 | $-6.59 | $-5.17 | $-18.75 | $-47.94 |
| 2020 | $-17.43 | $-29.94 | $-67.83 | $0.23 | $-94.89 |
| 2019 | $2.66 | $-18.99 | $-6.8 | $0.0 | $10.85 |
| 2018 | – | – | $36.64 | $2.52 | $35.89 |
| 2017 | – | – | – | – | $-6.44 |
| 2016 | – | – | – | – | $1.33 |
Business Profile of Organigram Holdings Inc.
Sector: Healthcare
Industry: Drug Manufacturers Specialty & Generic